title: Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia.
authors.forename: J
authors.initials: J
authors.lastname: Otten
authors.forename: L
authors.initials: L
authors.lastname: Schmitz
authors.forename: E
authors.initials: E
authors.lastname: Vettorazzi
authors.forename: A
authors.initials: A
authors.lastname: Schultze
authors.forename: A H
authors.initials: AH
authors.lastname: Marx
authors.forename: R
authors.initials: R
authors.lastname: Simon
authors.forename: J
authors.initials: J
authors.lastname: Krauter
authors.forename: S
authors.initials: S
authors.lastname: Loges
authors.forename: G
authors.initials: G
authors.lastname: Sauter
authors.forename: C
authors.initials: C
authors.lastname: Bokemeyer
authors.forename: W
authors.initials: W
authors.lastname: Fiedler
mesh_terms: D030301:Activin Receptors, Type II / Q000032:analysis; D000328:Adult; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000032:analysis*; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000032:analysis*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; C425364:ACVRL1 protein, human; D030301:Activin Receptors, Type II; D000077293:Receptor, Transforming Growth Factor-beta Type I; C000625841:TGFBR1 protein, human